Caseína quinasa

DEG-35 is a CRBN-dependent bifunctional degrader targeting IKZF2 and CK1α, with DC50 values of 1.4 nM and 4.4 nM for CK1α and IKZF2, respectively. It activates the p53 apoptotic pathway and is applicable for research related to acute myeloid leukemia (AML).

GSK-3β/CK-1δ-IN-1 (8d) is a dual inhibitor of GSK-3β and CK-1δ that can cross the blood-brain barrier, with IC50 values of 0.77 μM and 0.57 μM, respectively. GSK-3β/CK-1δ-IN-1 (8d) is applicable in neuroblastoma research.

CK1-IN-5 (compound B-AZ) is a CK1 inhibitor that extends the circadian rhythm period by inhibiting the activity of AtCKL3/AtCKL4.

KDX1381 is a bivalent CK2α inhibitor with an IC50 of 17 nM and a KD of 54 nM. It demonstrates antitumor activity in murine 786-O and A375 xenograft models. Furthermore, when combined with a vascular endothelial growth factor receptor (VEGFR) inhibitor or DNA-damaging agents, KDX1381 enhances antitumor effects in mouse hepatocellular carcinoma and glioma models.

IOR-160 is a dual inhibitor of casein kinase 2 (CK2) and HDAC. It exhibits high selectivity for CK2 with an IC50 of 1.7 nM and demonstrates broad inhibitory activity against HDAC (HDAC1, 2, 3, and 6) with IC50 values of 3.3 nM, 24.0 nM, 3.9 nM, and 13.0 nM, respectively, while showing low activity against HDAC8. IOR-160 modulates critical cell signaling pathways by inhibiting AKT phosphorylation and increasing α-tubulin acetylation. The compound reduces tumor growth and burden through its dual inhibition of CK2/HDAC and is relevant for research on triple-negative breast cancer.

Casein kinase1δ-IN-26 (compound 505) is a potent inhibitor of casein kinase 1δ. This compound is applicable in research related to neurodegenerative disorders such as Alzheimer’s disease.

Casein kinase1δ-IN-19 (compound 492) is a potent inhibitor of casein kinase 1δ. It is utilized in research related to neurodegenerative disorders, such as Alzheimer's disease.

CK2-IN-13 (compound 12c) is a potent inhibitor of CK2, with an IC50 value of 5.8 nM, playing a significant role in cancer research.

Casein kinase1δ-IN-25 (compound 487) is a potent inhibitor of casein kinase1δ. It is applicable in research on neurodegenerative diseases such as Alzheimer's disease.

CK1δ-IN-3 (compound 376) is a CK1δ (casein kinase 1δ) inhibitor that can be used to study neurodegenerative diseases such as Alzheimer's disease.

Dinoxyline is a potent dopamine receptor agonist, with dissociation constants (Ki values) for D1, D2, D3, and D4 receptors being 7 nM, 6 nM, 5 nM, and 43 nM, respectively. It is utilized in neuroscience research.

Casein kinase1δ-IN-13 (compound 401) is an inhibitor of Casein kinase1δ. It is utilized in the research of neurodegenerative diseases.

BMS-135 is a potent and selective ATP-competitive inhibitor of casein kinase 2 (CK2), with IC50 values of 0.8 nM for CK2α and 0.3 nM for CK2α' isoforms. It mimics the structure of ATP, binding to the active site of CK2 and inhibiting its serine/threonine phosphorylating activity. BMS-135 effectively inhibits cell proliferation and demonstrates antitumor properties, making it useful for research in colon cancer.

CK2-IN-12 (Compound 39) is an inhibitor of protein kinase CK2 with an IC₅₀ of 0.8 μM.

CK2 inhibitor4 (compound 5b) is a protein kinase CK2 inhibitor with an IC₅₀ of 3.8 μM. It is applicable in tumor research.

BAY-888 is capable of acting on CSNK1A1 (IC50: 1.5 nM) and CSNK1D (IC50: 5.5 nM).

(R,R)-BMS-986397 is a CK1α degrader with a DC50 ranging from 0.1 to 0.5 pM. This compound is applicable in leukemia research.

CK2-IN-10 (31) is an allosteric inhibitor of CK2, applicable in cancer research.

CK1δ-IN-10 (Compound 85) is an inhibitor of casein kinase 1 (CK1), specifically targeting CK1δ (CSNKID), with an IC50 value of 0.255 μM.

Casein kinase1δ-IN-31 (Compound 16) is an inhibitor of casein kinase (CK), specifically targeting CK1α, CK1δ, and p38α, with IC₅₀ values of 196 nM, 17 nM, and 18 nM, respectively. Additionally, Casein kinase1δ-IN-31 inhibits Double Homeobox 4 (DUX4) with an IC₅₀ of 1200 nM.